Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah Bower

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
New Medieval Literatures|September 25, 2018
Similes We Cure By: The Poetics of Late Medieval Medical TextsHannah Bower
Science Museum Group Journal|November 9, 2019
An Overlooked Eighteenth-Century Scrofula Pamphlet: Changing Forms and Changing Readers, 1760-1824Hannah Bower
Annals of the Rheumatic Diseases|February 18, 2025
Do newly approved drugs have a worse observed safety profile than once established? A study on time trends in risks of key safety outcomes with immunomodulatory drugs against rheumatoid arthritisViktor Molander, Hannah Bower, Thomas Frisell, et al.
Annals of the Rheumatic Diseases|October 9, 2020
Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from SwedenViktor Molander, Hannah Bower, Thomas Frisell, et al.
Rheumatology (Oxford, England)|July 29, 2021
Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practiceViking Huss, Hannah Bower, Hjalmar Wadström, et al.
Annals of the Rheumatic Diseases|March 3, 2023
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort studyViking Huss, Hannah Bower, Karin Hellgren, et al.
Annals of the Rheumatic Diseases|November 23, 2021
Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, et al.
RMD Open|November 23, 2023
Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritisHannah Bower, Thomas Frisell, Daniela di Giuseppe, et al.
British Journal of Cancer|January 24, 2018
Loss in working years after a breast cancer diagnosisAnna Plym, Hannah Bower, Irma Fredriksson, et al.
Annals of the Rheumatic Diseases|September 23, 2022
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritisViktor Molander, Hannah Bower, Thomas Frisell, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
New Medieval Literatures|September 25, 2018
Similes We Cure By: The Poetics of Late Medieval Medical TextsHannah Bower
Science Museum Group Journal|November 9, 2019
An Overlooked Eighteenth-Century Scrofula Pamphlet: Changing Forms and Changing Readers, 1760-1824Hannah Bower
Annals of the Rheumatic Diseases|February 18, 2025
Do newly approved drugs have a worse observed safety profile than once established? A study on time trends in risks of key safety outcomes with immunomodulatory drugs against rheumatoid arthritisViktor Molander, Hannah Bower, Thomas Frisell, et al.
Annals of the Rheumatic Diseases|October 9, 2020
Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from SwedenViktor Molander, Hannah Bower, Thomas Frisell, et al.
Rheumatology (Oxford, England)|July 29, 2021
Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practiceViking Huss, Hannah Bower, Hjalmar Wadström, et al.
Annals of the Rheumatic Diseases|March 3, 2023
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort studyViking Huss, Hannah Bower, Karin Hellgren, et al.
Annals of the Rheumatic Diseases|November 23, 2021
Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, et al.
RMD Open|November 23, 2023
Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritisHannah Bower, Thomas Frisell, Daniela di Giuseppe, et al.
British Journal of Cancer|January 24, 2018
Loss in working years after a breast cancer diagnosisAnna Plym, Hannah Bower, Irma Fredriksson, et al.
Annals of the Rheumatic Diseases|September 23, 2022
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritisViktor Molander, Hannah Bower, Thomas Frisell, et al.
Pageof 4